Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Completed · Phase 3

Conditions studied: Non-Squamous Cell Non-small Cell Lung Cancer

In brief

The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy

Key facts

Study ID

NCT01673867

Run by

Bristol-Myers Squibb

People needed

582

Starts

2012-11-02

Expected to finish

2021-12-17

Last updated by the study team

2023-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men \& women ≥18 years of age
• Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease
• Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease
• Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
• Eastern Cooperative Oncology Group (ECOG) performance status ≤1
• A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient

You may not qualify if…

• Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent)
• Subjects with carcinomatous meningitis
• Subjects with active or recent history of known or suspected autoimmune disease. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll
• Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization
• Prior therapy with anti-programmed death-1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), anti-programmed cell death ligand 2 (anti-PD-L2), anti-cluster of differentiation 137 (anti-CD137), or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• Prior treatment with Docetaxel
• Treatment with any investigational agent within 14 days of first administration of study treatment
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0009 — Duarte, California, United States
• Local Institution - 0042 — San Diego, California, United States
• San Francisco Oncology Associates — San Francisco, California, United States
• Yale University — New Haven, Connecticut, United States
• Local Institution - 0034 — Tampa, Florida, United States
• Northwest Georgia Oncology Center, P.C. — Marietta, Georgia, United States
• Local Institution - 0030 — Chicago, Illinois, United States
• The Johns Hopkins University — Baltimore, Maryland, United States
• Local Institution - 0031 — Boston, Massachusetts, United States
• Local Institution - 0040 — Boston, Massachusetts, United States
• Local Institution - 0138 — Boston, Massachusetts, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Local Institution - 0008 — Mineola, New York, United States
• Local Institution - 0020 — New York, New York, United States
• Local Institution - 0027 — Durham, North Carolina, United States
• Local Institution - 0026 — Cincinnati, Ohio, United States
• St. Mary Medical Center — Langhorne, Pennsylvania, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Local Institution - 0035 — Sayre, Pennsylvania, United States
• Local Institution - 0025 — Columbia, South Carolina, United States
• Local Institution - 0024 — Chattanooga, Tennessee, United States
• Local Institution - 0028 — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Local Institution - 0033 — Dallas, Texas, United States
• Mayo Clinic Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.